Use of a Standardized MxA Protein Measurement-Based Assay for Validation of Assays for the Assessment of Neutralizing Antibodies Against Interferon-β-Reference-Cited by-同舟云学术

Use of a Standardized MxA Protein Measurement-Based Assay for Validation of Assays for the Assessment of Neutralizing Antibodies Against Interferon-β

Published:2013-11 Issue:11 Volume:33 Page:660-671
ISSN:1079-9907
Container-title:Journal of Interferon & Cytokine Research
language:en
Short-container-title:Journal of Interferon & Cytokine Research

Author:

Wadhwa Meenu¹,Subramanyam Meena²,Goelz Susan²,Goyal Jaya²,Jethwa Vijay²,Jones Wendy²,Files James G.³,Kramer Daniel⁴,Bird Chris¹,Dilger Paula¹,Tovey Michael⁵,Lallemand Christophe⁵,Thorpe Robin¹

Affiliation:

1. Biotherapeutics Group, National Institute for Biological Standards and Control, Hertfordshire, United Kingdom.

2. Biogen Idec, Development Translational Medicine, Cambridge, Massachusetts.

3. Berlex, Bayer Healthcare, Richmond, California.

4. Merck KGaA, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany.

5. Laboratory of Biotechnology and Applied Pharmacology, Ecole Normale Supérieure de Cachan, Cachan Cedex, France.

Publisher

Mary Ann Liebert Inc

Subject

Virology,Cell Biology,Immunology

Link

http://www.liebertpub.com/doi/pdf/10.1089/jir.2012.0079

Reference47 articles.

1. Antibodies against interferon-beta in multiple sclerosis

2. Implications of neutralising antibodies on therapeutic efficacy

3. Focal Cortical Dysplasia

4. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bioanalytical Methods to Detect Preexisting and Post‐administration Humoral Immune Responses Against AAV Capsid Proteins;Drug Development for Gene Therapy;2024-02-16

2. Interferon score is increased in incomplete systemic lupus erythematosus and correlates with myxovirus-resistance protein A in blood and skin;Arthritis Research & Therapy;2019-12

3. Harmonization and standardization of immunogenicity assessment of biotherapeutic products;Bioanalysis;2019-09

4. Neutralizing antibody production against Rebif® and ReciGen® in Relapsing-Remitting Multiple Sclerosis (RRMS) patients and its association with patient's disability;International Immunopharmacology;2018-09

5. Interaction of PEGylated interferon-beta with antibodies to recombinant interferon-beta;International Immunopharmacology;2018-09